NICE rejects Eisai's Halaven for breast cancer; AZ nears EU nod on thyroid cancer med;

@FiercePharma: Counterfeiting tricks emerge in Chinese crackdown. E.g., to make fake little blue pills blue, add printer ink. News | Follow @FiercePharma

> U.K. cost-effectiveness regulators said they wouldn't recommend Eisai's new breast cancer treatment Halaven for use on the National Health Sevice, saying its survival benefit didn't outweigh increased side effects. Story

> The GAVI Alliance said it would be making human papillomavirus vaccines, such as Merck's ($MRK) Gardasil and GlaxoSmithKline's ($GSK) Cervarix, available to women and girls in poor countries. Report

> AstraZeneca ($AZN) has won a positive opinion from European regulators for approval of its thyroid cancer treatment Caprelsa. Item

> Johnson & Johnson ($JNJ) plans to phase out a formaldehyde-releasing chemical now used in its baby shampoos, soaps and other products, after a report on the chemicals touched off public criticism. News

> Pharmacy benefits manager SXC Health Solutions will buy the privately held HealthTrans for $250 million to broaden its reach in the PBM market. Article

> Slovenian drugmaker Krka reported a 4% decline in 9-months profits to $156 million because of currency effects. The company is planning a new listing on the Warsaw stock exchange by mid-year 2012. Piece

> As AstraZeneca  ($AZN) nears the closure of its site in Charnwood, England, the company says 90% of workers losing their jobs have "secured their future." News

> Clinical trials for new CV meds often test them as add-ons for statins, excluding patients who can't tolerate the widely used cholesterol fighters, so additional trials are needed, researchers said. Report

Biotech News

@FierceBiotech: FDA delays review of key Takeda diabetes drug and Actos combo. Item | Follow @FierceBiotech

@MaureenFierce: Sad: US seniors having to pay more for their Rx drugs, according to a new study. Story | Follow @MaureenFierce

 @MarkHFierce: So Russia plans to be a global device competitor by 2020? Hmmm.... Release | Follow @MarkHFierce

> AstraZeneca wins EMA backing for thyroid cancer drug. Report

> FDA delays review of key Takeda diabetes drug, Actos combo. Story

And Finally... Facebook and other social media are making it easier for vaccination-averse parents to arrange "pox parties" to expose kids to chickenpox infection. More

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.